>>3 Dividend Stocks for a Richer Retirement<< (sponsored)
ETF Channel ETF Channel ETF holdings and exposure research

LABU's Holdings Imply 58% Gain Potential


Joel Kornblau, Editor, ETF Channel - Thursday, July 10, 2025, 6:58 AM

From their well lit penthouse office desk, an ETF trader follows four exchange traded funds across different monitors showing candlestick charts, with city views visible through the window beyond.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Direxion Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $105.45 per unit.

With LABU trading at a recent price near $66.95 per unit, that means that analysts see 57.51% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of LABU's underlying holdings with notable upside to their analyst target prices are IDEAYA Biosciences Inc (IDYA), Denali Therapeutics Inc (DNLI), and Replimune Group Inc (REPL). Although IDYA has traded at a recent price of $22.97/share, the average analyst target is 122.36% higher at $51.08/share. Similarly, DNLI has 116.89% upside from the recent share price of $15.00 if the average analyst target price of $32.53/share is reached, and analysts on average are expecting REPL to reach a target price of $21.88/share, which is 110.54% above the recent price of $10.39. Below is a twelve month price history chart comparing the stock performance of IDYA, DNLI, and REPL:

IDYA, DNLI, and REPL Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
Direxion Daily S&P Biotech Bull 3X Shares ETF LABU $66.95 $105.45 57.51%
IDEAYA Biosciences Inc IDYA $22.97 $51.08 122.36%
Denali Therapeutics Inc DNLI $15.00 $32.53 116.89%
Replimune Group Inc REPL $10.39 $21.88 110.54%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on IDYA — FREE
Get the latest Zacks research report on DNLI — FREE
Get the latest Zacks research report on REPL — FREE



« Back

Featured ETF Research

Browse ETF screens, holdings-related research, dividend and yield pages, analyst screens, and related market idea pages from across the channel network. These links are grouped by topic to make the list easier to scan.

Dividend, Yield, and Income Research

Dividend and income-oriented screens that are relevant to ETF investors comparing holdings, yield exposure, and stock selection ideas.

Energy, Metals, and Canada Research

Cross-network sector research pages that may be useful for investors following ETF exposure to energy, metals, and Canadian markets.

Featured News Links

LABU's Holdings Imply 58% Gain Potential | www.ETFChannel.com | Copyright © 2009 - 2026, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.